Sanofi Sponsored ADR Aktie News

Sanofi has breached the UK pharma code of practice with unsubstantiated claims that its Beyfortus was more effective than Pfizer's RSV vaccine, the industry's self-regulatory body said on Monday, responding to a complaint.

French drugmaker Sanofi said on Monday that its experimental genetic disorder treatment showed promise in a late-stage study of patients with a type of Gaucher disease, but failed to meet the main goal in a separate trial.

Sanofi's Rezurock recommended for EU approval by the CHMP to treat chronic graft-vs-host disease Recommendation supported by safety and efficacy results from several clinical studies and real-world evidence If approved, Rezurock would offer a new treatment option in the EU for adult patients and in children aged 12 years and older in late line chronic GVHD Paris, January 30, 2026. The European ...

Sanofi (SAN:CA) Q4 2025 Earnings Call Transcript

Sanofi stock rose slightly early Thursday on better-than-expected earnings and in line guidance for the current year.

Drugmakers Roche and Sanofi posted full-year earnings that matched expectations and did little to move either stock. As pharma companies face a "patent cliff" where existing drugs lose exclusivity, the companies talked up what they have in the pipeline.

The buyback comes as the French drugmaker said that its sales and earnings for the fourth quarter rose.

French drugmaker Sanofi said on Thursday it expects sales to grow by a high-single-digit percentage in 2026, banking on strong demand for its blockbuster asthma drug Dupixent and some newer medicines.